1734 — Sinphar Pharmaceutical Co Cashflow Statement
0.000.00%
Last trade - 00:00
- TWD5.99bn
- TWD7.15bn
- TWD2.96bn
- 35
- 46
- 47
- 35
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -86.7 | -118 | -185 | 245 | 306 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 18.5 | 18.7 | 25.1 | 23.3 | -42.4 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -248 | -5 | 25.5 | -110 | -210 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -79.5 | 146 | 136 | 425 | 296 |
Capital Expenditures | -177 | -158 | -161 | -153 | -301 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -34.1 | -7.91 | -44.2 | 29.2 | -33.6 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -211 | -166 | -206 | -124 | -335 |
Financing Cash Flow Items | -38.4 | 92.6 | 160 | -10.7 | 15.2 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 182 | 319 | 123 | -263 | -121 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -118 | 303 | 51 | 42.8 | -163 |